^
Association details:
| Biomarker: | ALK V1180L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib
Excerpt:
Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response.
DOI:
10.1158/1078-0432.CCR-14-1511
